Manejo post-yodo y post-cirugía de enfermedad tiroidea benigna. Revisión narrativa y algoritmo de manejo

El hipertiroidismo primario es una condición que requiere manejo idealmente definitivo, los medicamentos antitiroideos son una opción viable y no invasiva, pero con la desventaja de ser curativa solo en el 30% de los casos y en casos de intolerancia, ausencia de respuesta o efectos secundarios se requiere manejo definitivo con yodo radioactivo o cirugía.

Con frecuencia los pacientes son llevados a estas terapias definitivas, sin embargo, hay evidencia divergente sobre las pautas de seguimiento posterior al manejo quirúrgico o post-yodo, sin protocolos establecidos en muchas instituciones. Por lo anterior, se realizó una revisión del tema y un protocolo con el fin de homogenizar el conocimiento y ser una guía para el manejo post terapia de los pacientes hipertiroideos llevados a tratamiento definitivo.

 

. De Leo, Lee SY, Braverman LE. Hyperthyroidism. Lancet.2016; 388: 906-18.

Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol.2018;14: 301–16.

Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH T(4) and thyroid antibodies in the United States population: NHANES III. J. Clin. Endocrinol. Metab. 2002; 87:489–99.

Chaves W. Amador D. Tovar H. Prevalencia de la disfunción tiroidea en la población adulta mayor de consulta externa. Acta Med Colomb.2018; 43 (1): 24-30.

Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med. 1994; 121:281–88.

Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine: a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab. 1996;81(8):2986-93.

Boelaert K. Treatment of Graves' disease with antithyroid drugs: current perspectives. Thyroid. 2010;20:943–46.

Van Soestbergen MJ, Van der Vijver JC, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves' disease. J Endocrinol Invest. 1992;15(11):797-800.

Franklyn JA. The management of hyperthyroidism. N Engl J Med. 1994; 330(24):1731-8.

Mumtaz M, Lin LS, Hui KC, Mohd Khir AS. Radioiodine I-131 for the therapy of graves' disease. Malays J Med Sci. 2009;16(1):25–33.

Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2002;87(3):1073-7.

Aljenaee K, Ali S, Cooke J, Phelan N, Pazderska N, Healy L. Early and More Frequent Monitoring of Thyroid Function Tests (TFTs) Post-RAI Could Be Clinically Beneficial. J Endocr Soc. 2019;3:592.

Tamagna EI, Levine GA, Hershman JM. Thyroid-hormone concentrations after radioiodine therapy for hyperthyroidism. J Nucl Med. 1979;20:387-91.

Kreisig T, Abenhardt W, Mann K, Kirsch CM, Moser E. Early changes in thyroid hormones following radioiodine therapy of hyperthyroidism with reference to etiology and accompanying medication. Klin Wochenschr. 1989;67(7):386-92.

Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves’ disease. Am J Med. 1995; 99:173–79.

Ross D, Burch H,Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26 (10): 1343-421.

Ahmad T, Khoja A, Haroon N, Ashfaq MA. Outcome of radioactive iodine therapy in Toxic Nodular Goiter in Pakistan. Pak J Med Sci. 2018; 34(5): 1146–51.

Mandel S. Larsen PR. Davies TF. (2011). Thyrotoxicosis. En: Williams. Tratado de endocrinología (pp 362-405). España: ELSEVIER.

Schäffler A. Hormone replacement after thyroid and parathyroid surgery. Dtsch Arztebl Int. 2010;107(47):827–34.

Franklyn JA. The management of hyperthyroidism. N Engl J Med. 1994;330(24):1731-8.

Shafer RB, Nuttal FQ. Thyroid crisis induced by radioactive iodine. J Nul Med.1971; 12:262-64.

Sheehan M. Doi S. Transient Hypothyroidism after Radioiodine for Graves’ Disease: Challenges in Interpreting Thyroid Function Tests, Clin Med Res. 2016; 14(1): 40–5.

Oszukowska L. Knapska M. Lewi?ski A. Effects of drugs on the efficacy of radioiodine (131|) therapy in hyperthyroid patients. Arch Med Sci. 2010; 6(1): 4–10.

Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, et al. Effects of antithyroid drugs on radioiodine treatment: Systematic review and meta-analysis of randomized controlled trials. BMJ. 2007;334:514.

Smith T, Hegedus L. Graves'disease. N Engl J Med. 2016.20;375(16):1552-65.

Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab. 1999;84:1229-33.

Kartamihardja AH, Massora S. The Influence of Antithyroid Drug Discontinuation to the Therapeutic Efficacy of (131)I in Hyperthyroidism. World J Nucl Med. 2016;15(2):81-4.

Mijnhout GS, Franken AAM. Antithyroid drug regimens before and after 131I-therapy for hyperthyroidism: evidence-based?. Neth J Med. 2008;66(6):238-41.

Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves’ ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid. 2013; 23:620–25.

DeGroot LJ. Diagnosis and Treatment of Graves’ Disease. Endotext (internet). 2016. Consultado 22 Jul 2020, Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK285548.

Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine Treatment of Hyperthyroidism Prognostic Factors for Outcome. JCEM.2001; 86 (8): 3611–17.

Leech NJ, Dayan CM. Controversies in the management of Graves’ disease. Clin Endocrinol. 1998;49:273–80.

Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States. World J Surg.2010; 34: 1261–64.

Sadler GP, Clark OH, Van Heerden JA, Farley DR. (1999). Thyroid and parathyroid. En: Schwartz Principles of surgery. (pp 1661-713). New York: McGraw-Hill.

Alsanea O, Clark O. Treatment of Graves’ disease: the advantages of surgery. Endocrinol

Metab Clin North Am 2000;29(2):321–35.

Rangaswamy M, Padhy AK, Gopinath PG, Shukla NK, Gupta K, Kapoor MM.Effect of Lugol's iodine on the vascularity of thyroid gland in hyperthyroidism. Nucl Med Commun. 1989;10(9):679-84.

Pattou F, Combemale F, Fabre S, Carnaille B, Decoulx M, Wemeau JL. Hypocalcemia following

thyroid surgery: incidence and prediction of outcome. World J Surg. 1998;22:718–24.

Lo CY, Luck JM, Sidney CT. Applicability of intraoperative parathyroid hormone assay

during thyroidectomy. Ann Surg. 2002;236(5):564–9.

Husein M, Hier MP, Al-Abdulhadi K, Black M.Predicting calcium status post thyroidectomy with early calcium levels. Otolaryngol Head Neck Surg. 2002; 127:289–93.

Bellantone R, Lombardi CP, Raffaelli M, Boscherini M, Alesina PF, De Crea C, et al. Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy?. Surgery. 2002; 132:1109-11.

Langley RW, Burch HB. Perioperative management of the thyrotoxic patient. Endocrinol

Metab Clin North Am. 2003;32(2):519–34.

Roos A, Linn-Rasker SP, van Domburg RT, Tijssen JP, Berghout A. et al. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. Arch Intern Med. 2005; 165:1714-20.

Boger MS, Perrier ND. Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin North Am. 2004;84(3):849-74.

East HE. Ahmad S. Koch CA. Hormone Replacement Following Thyroidectomy. Encyclopedia of Otolaryngology, Head and Neck Surgery. Springer.2013: 1997-1202.

Boger MS, Perrier ND. Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin North Am. 2004;84(3):849-74.

Piantanida E. Preoperative management in patients with Graves’ disease. Gland Surg. 2017; 6(5): 476–81.

Ojomo K, Schneider DF, Reiher AE, Lai N, Schaefer S, Chen H, et al. Using BMI to Predict Optimal Thyroid Dosing Following Thyroidectomy. J Am Coll Surg. 2013; 216 (3): 454-60.

Smithson M, Asban A, Miller J, Chen H. Considerations for Thyroidectomy as Treatment for Graves Disease. Clin Med Insights Endocrinol Diabetes. 2019;12: 1-5.

Lowney JK, Lairmore TC. (2002). Endocrine surgery. En: Washington manual of surgery. (pp 862-76). St Louis: Lippincott.

Xing T, Hu Y, Wang B, Zhu J. Role of oral calcium supplementation alone or with vitamin D in preventing post-thyroidectomy hypocalcaemia: A meta-analysis. Medicine.2019; 98(8): e14455.

Adherencia a medicación
mortalidad
hospitalización
diabetes mellitus tipo 2
hipoglicemiantes